Kymera Therapeutics Inc. (KYMR)
31.05
-0.30 (-0.96%)
At close: Mar 03, 2025, 12:15 PM
Kymera Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 |
| Revenue | 47.07M | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M | n/a |
| Cost of Revenue | n/a | 189.08M | 2.98M | 2.4M | 62.1M | 825K | 205K |
| Gross Profit | 47.07M | -110.49M | 43.85M | 70.44M | -28.07M | 2.11M | -205K |
| Operating Income | -261.63M | -165.53M | -161.26M | -100.53M | -46.3M | -42.2M | -21.45M |
| Interest Income | 38.03M | 18.76M | 6.62M | 488K | 826K | 1M | n/a |
| Pretax Income | -223.86M | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Net Income | -223.86M | -146.96M | -151.83M | -98M | -43.95M | -41.29M | -21.47M |
| Selling & General & Admin | 63.53M | 55.04M | 43.83M | 36.34M | 18.23M | 7.98M | 3.77M |
| Research & Development | 240.25M | 189.08M | 164.25M | 137.02M | 62.1M | 37.16M | 17.68M |
| Other Expenses | 4.92M | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 308.71M | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Interest Expense | 249K | 196K | 176K | 175K | 115K | 46K | 16K |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 308.71M | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| Income Tax | n/a | n/a | -2.98M | -2.22M | -1.65M | 46K | 43.86K |
| Shares Outstanding (Basic) | 75.04M | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
| Shares Outstanding (Diluted) | 75.04M | 58.37M | 53.93M | 47.99M | 17.35M | 44.53M | 44.53M |
| EPS (Basic) | -2.98 | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EPS (Diluted) | -2.98 | -2.52 | -2.82 | -2.04 | -2.53 | -0.93 | -0.48 |
| EBITDA | -216.24M | -143.2M | -151.66M | -97.64M | -43.72M | -40.38M | -21.25M |
| Depreciation & Amortization | 7.37M | 3.56M | 2.98M | 2.4M | 1.76M | 825K | 205K |